Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 11/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.46 |
| ▸ | CCR3 | P51677 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | FASN | P49327 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3287727 | 1.00 | ADRB3 (0.50) | ADRB3HRH1CCR3MEN1KMT2A | |
| SCHEMBL4805698 | 0.90 | ADRB3 (0.54) | ADRB3ADRB1ADRB2 | |
| SCHEMBL4805686 | 0.90 | ADRB3 (0.54) | ADRB3ADRB1ADRB2 | |
| SCHEMBL4805693 | 0.90 | ADRB3 (0.54) | ADRB3ADRB1ADRB2 | |
| SCHEMBL3286920 | 0.89 | ADRB3 (0.54) | ADRB3MEN1KMT2AADRB1LMNA | |
| SCHEMBL3286919 | 0.89 | ADRB3 (0.54) | ADRB3MEN1KMT2AADRB1LMNA | |
| SCHEMBL4804960 | 0.88 | ADRB3 (0.50) | ADRB3MEN1KMT2AADRB1ALDH1A1 | |
| SCHEMBL4804931 | 0.88 | ADRB3 (0.50) | ADRB3MEN1KMT2AADRB1ALDH1A1 | |
| SCHEMBL3286941 | 0.87 | ADRB3 (0.53) | ADRB3ADRB1ADRB2 | |
| SCHEMBL3286937 | 0.87 | ADRB3 (0.53) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718646-B2 | Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2010-05-18 | — | — | US | claimed |
| US-20080261949-A1 | ethyl 4-[4-(2-hydroxy-3-(4-hydroxy-3-(methylsulphonylamino)phenoxy)propylamino)cyclohexyl]benzoic acid; beta-3 adrenergic receptor agonist; tocolytics; delaying preterm birth; antidiabetic; obesity; oxyalkylation of the phenyl(alkyl)cyclohexyl(alkyl)amine with a glycidyl ether | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | claimed |
| US-7419974-B2 | Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-09-02 | — | — | US | claimed |
| EP-1341753-B1 | CYCLOHEXYL(ALKYL)-PROPANOLAMINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2007-09-26 | — | — | EP | claimed |
| US-20070015745-A1 | Cyclohexyl(alkyl)propanolamines, Preparation Method and Pharmaceutical Compositions Containing Same | SANOFI-AVENTIS (FR) | 2007-01-18 | — | — | US | claimed |
| US-7718646-B2 | Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2010-05-18 | — | — | US | disclosed |
| US-20080261949-A1 | ethyl 4-[4-(2-hydroxy-3-(4-hydroxy-3-(methylsulphonylamino)phenoxy)propylamino)cyclohexyl]benzoic acid; beta-3 adrenergic receptor agonist; tocolytics; delaying preterm birth; antidiabetic; obesity; oxyalkylation of the phenyl(alkyl)cyclohexyl(alkyl)amine with a glycidyl ether | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| US-7419974-B2 | Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-09-02 | — | — | US | disclosed |
| US-7388031-B2 | Cyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-06-17 | — | — | US | disclosed |
| EP-1341753-B1 | CYCLOHEXYL(ALKYL)-PROPANOLAMINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2007-09-26 | — | — | EP | disclosed |
| US-20070015745-A1 | Cyclohexyl(alkyl)propanolamines, Preparation Method and Pharmaceutical Compositions Containing Same | SANOFI-AVENTIS (FR) | 2007-01-18 | — | — | US | disclosed |
| US-20040053916-A1 | Cyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same | SANOFI (FR) | 2004-03-18 | — | — | US | disclosed |
| EP-1341753-A1 | CYCLOHEXYL(ALKYL)-PROPANOLAMINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Sanofi-Aventis (FR) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002044139-A1 | CYCLOHEXYL(ALKYL)-PROPANOLAMINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261949-A1 | ethyl 4-[4-(2-hydroxy-3-(4-hydroxy-3-(methylsulphonylamino)phenoxy)propylamino)cyclohexyl]benzoic acid; beta-3 adrenergic receptor agonist; tocolytics; delaying preterm birth; antidiabetic; obesity; oxyalkylation of the phenyl(alkyl)cyclohexyl(alkyl)amine with a glycidyl ether | ADRB3, FFAR3, ADRB2 | ADRB3 1/4885HRH1 389/4885CCR3 1016/4885 |
| US-20070015745-A1 | Cyclohexyl(alkyl)propanolamines, Preparation Method and Pharmaceutical Compositions Containing Same | C5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R | ADRB3 24/4885HRH1 27/4885CCR3 142/4885 |
| US-20040053916-A1 | Cyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ADRA2C, ADRA1A | ADRB3 16/4885HRH1 118/4885CCR3 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.